Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group

Clinical and Experimental Rheumatology

Volumn 25, Issue 5, 2007, Pages 722-727

  Airò, Paolo ^b   Rossi, Mara ^a   Scarsi, Mirko ^b   Danieli, Elisabetta ^b   Grottolo, Alberto ^a   Zambruni, Alberto ^a  

^a Spedali Civili   (Italy)

^b Rheumatology and Clinical Immunology   (Italy)

Author keywords

Iloprost; Lung function test; Pulmonary arterial hypertension; Survival; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ILOPROST; METHOTREXATE; PENICILLAMINE; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SCLERODERMA; SURVIVAL; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RAYNAUD DISEASE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; ULCER;

EID: 37349032875     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. MCHUGH NJ, CSUKA M, WATSON H et al.: Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988; 47: 43-7.
2. WIGLEY FM, WISE RA, SEIBOLD JR et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199-206.
3. DELLA BELLA S, MOLTENI M, MASCAGNI B, ZULIAN C, COMPASSO S, SCORZA R: Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 1997; 15: 135-41.
4. BIASI D, CARLETTO A, CARAMASCHI P et al.: Iloprost as cyclic five-days infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year. Rev Rhum (English ed.) 1998; 65: 745-50.
5. FILACI G, CUTOLO M, SCUDELETTI M et al.: Cyclosporin and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 1999; 38: 992-6.
6. SCORZA R, CARONNI M, MASCAGNI B et al.: Effects of long-term cyclic iloprost therapy in Systemic Sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19: 503-8.
7. BETFONI L, GERI A, AIRÒ P et al.: Systemic sclerosis therapy with iloprost. A prospective observational study of 30 patients treated for a median time of 3 years. Clin Rheumatol 2002; 21: 244-50.
8. MILIO G, CORRADO E, GENOVA C et al.: Iloprost treatment in patients with Raynaud phenomenon secondary to systemic sclerosis and the quality of life: A new therapeutic protocol. Rheumatology 2006; 45: 999-1004.
9. KRAUSE W, KRAIS TH: Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986; 30: 61-8.
10. LEROY EC, BLACK C, FLEISCHMAYER R et al.: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-8.
11. MEDSGER TA JR, STEEN VD: Classification, prognosis. In: CLEMENTS PJ and FURST DE (Eds.): Systemic Sclerosis. 2nd ed. Philadelphia, Lippincott Williams & Wilkins, 1996; 51-79.
12. AIRÒ P, DANIELI E, PARRINELLO G et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience with and review of the literature with pooled analysis of lung function tests. Clin Exp Rheumatol 2004; 22: 573-8.
13. AIRÒ P, DANIELI E, ROSSI M et al.: Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: Results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007; 25: 293-6.
14. VALENTINI G, MEDSGER TA JR, SILMAN AJ, BOMBARDIERI S (Eds.): The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003; Suppl. 29: S1-S56.
15. CLEMENTS P, LACHENBRUCH P, SIEBOLD J et al.: Inter- and intra-observer variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1277-80.
16. POOLE JL, STEEN VD: The use of the Health Assessment Questionnaire to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 27-31.
17. COTES JE, CHINN DJ, ROCA J, QUANJER PH, YERNAULT JC: Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J 1993; 16 (Suppl.): 41-52.
18. QUANJER PH, TAMMERLING GJ, COTES JE, PEDERSEN OF, PESLIN R, YERNAULT JC: Lung volumes and forced ventilatory flows. Rev Mal Respir 1994; 11: 5-40.
19. NICOLINI FA, MEHTA P, LAWSON D, MEHTA JL: Reduction in human neutrophil chemotaxis by prostacyclin analogue iloprost. Thrombosis Res 1990; 59: 669-74.
20. RIVA CM, MORGANROTH ML, MARKS RM, TODD RF, WARD PA: Iloprost inhibits activated human neutrophil (PMN) adherence to endothelial cells via increased cyclic AMP. Clin Res 1989; 37: 949A-954A.
21. DELLA BELLA S, MOLTENI M, MOCELLIN C, FUMAGALLI S, BONARA P, SCORZA R: Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins 2001; 65: 73-83.
22. BERTELE' V, MUSSONI L, DEL ROSSO G: Detective fibrinolytic response in atherosclerotic patients - effect of iloprost and its possible mechanism of action. Thromb Haemost 1988; 60: 141-4.
23. STRATTON R, SHIWEN X, MARTINI G et al.: Iloprost suppresses connective tissue growth factor production in fibroblast and skin of the scleroderma patients J Clin Invest 2001; 108; 241-50.
24. CARAMASCHI P, BIASI D, FERRARI M et al.: Long-term evaluation of lung function in patients affected by sclerodermia treated with cyclic iloprost infusions. Rheumatol Int 2005; 25: 250-4.
25. CARAMASCHI P, VOLPE A, TINAZZI I, BAMBARA LM, CARLETTO A, BIASI D: Does cyclically iloprost infusion prevent isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 2006; 26: 902-7.
26. THURM CA, WIGLEY FM, DOLE WP, WISE RA: Failure of vasodilatator infusion to alter pulmonary diffusing capacity in systemic sclerosis. Am J Med 1991; 90: 547-52.
27. STEEN VD, MEDSGER TA JR: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
28. SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al.: Anti-remodelling effect of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94: 1101-8.